EMA workshop on immune thrombocytopenia
EMA is organising a workshop on immune thrombocytopenia to have a multi-stakeholder’s perspective on the challenges in drug development, regulation and clinical practice in this disease. This is in line with the clinical domain working party work plan for 2026.
The aims of the workshop are:
- To present the epidemiology and disease background in adults and children with immune thrombocytopenia, the current international treatment guidelines, the unmet medical need, and the overview of the authorised medicines/treatments for immune thrombocytopenia;
- To present the challenges in treatment/drug development from a clinicians’, patients, and regulator´s perspective with regards to study design, objectives and endpoints used in clinical trials.
The workshop outcomes will support the next update of the Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia
Participants can register for online participation until 22 June 2026 via this link: EMA workshop on Challenges in drug development, regulation and clinical practice in immune thrombocytopenia